Cargando…

Amrubicin in previously treated patients with malignant pleural mesothelioma: A phase II study

BACKGROUND: The aim of this study was to assess the efficacy and safety of amrubicin for previously treated malignant pleural mesothelioma. METHODS: The eligibility criteria were: previously treated unresectable malignant pleural mesothelioma; performance status 0–1; age ≤ 75; adequate hematological...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ikeda, Takaya, Takemoto, Shinnosuke, Senju, Hiroaki, Gyotoku, Hiroshi, Taniguchi, Hirokazu, Shimada, Midori, Dotsu, Yosuke, Umeyama, Yasuhiro, Tomono, Hiromi, Kitazaki, Takeshi, Fukuda, Masaaki, Soda, Hiroshi, Yamaguchi, Hiroyuki, Fukuda, Minoru, Mukae, Hiroshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons Australia, Ltd 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7327919/ https://www.ncbi.nlm.nih.gov/pubmed/32462731 http://dx.doi.org/10.1111/1759-7714.13490

Ejemplares similares

Phase II study of ramucirumab and docetaxel for previously treated non‐small cell lung cancer patients with malignant pleural effusion: Protocol of PLEURAM study
por: Takemoto, Shinnosuke, et al.
Publicado: (2019)

Phase II study of nedaplatin and amrubicin as first‐line treatment for advanced squamous cell lung cancer
por: Taniguchi, Hirokazu, et al.
Publicado: (2019)

Real-World Incidence of Febrile Neutropenia among Patients Treated with Single-Agent Amrubicin: Necessity of the Primary Prophylactic Administration of Granulocyte Colony-Stimulating Factor
por: Dotsu, Yosuke, et al.
Publicado: (2021)

Three distinct mechanisms underlying human γδ T cell-mediated cytotoxicity against malignant pleural mesothelioma
por: Umeyama, Yasuhiro, et al.
Publicado: (2023)

Phase I study of amrubicin plus cisplatin and concurrent accelerated hyperfractionated thoracic radiotherapy for limited‐disease small cell lung cancer: protocol of ACIST study
por: Akagi, Kazumasa, et al.
Publicado: (2022)

Immunosuppressive tumor microenvironment in extraskeletal myxoid chondrosarcoma: A case of pleural metastases
por: Ogata, Ryosuke, et al.
Publicado: (2022)

Phase I study of pemetrexed and concurrent radiotherapy for previously untreated elderly patients with locally advanced non‐squamous non‐small cell lung cancer
por: Takemoto, Shinnosuke, et al.
Publicado: (2017)

Phase II study of IRInotecan treatment after COmbined chemo‐immunotherapy for extensive‐stage small cell lung cancer: Protocol of IRICO study
por: Tomono, Hiromi, et al.
Publicado: (2023)

Efficacy of S‐1 after pemetrexed in patients with non‐small cell lung cancer: A retrospective multi‐institutional analysis
por: Takemoto, Shinnosuke, et al.
Publicado: (2021)

Hypertrophic osteoarthropathy associated with lung cancer: Possible links among hypoxia‐inducible factor‐1α, vascular endothelial growth factor, and hypervascularization
por: Tagawa, Ryuta, et al.
Publicado: (2023)

Pulmonary Artery Sarcoma Overexpressing Platelet-derived Growth Factor Receptor α
por: Takemoto, Shinnosuke, et al.
Publicado: (2017)

Dabrafenib and trametinib therapy in an elderly patient with non‐small cell lung cancer harboring the BRAF V600E mutation
por: Dotsu, Yosuke, et al.
Publicado: (2020)

Genetic profile of thymic epithelial tumors in the Japanese population: an exploratory study examining potential therapeutic targets
por: Shimada, Midori, et al.
Publicado: (2023)

Remarkable response to pembrolizumab with platinum‐doublet in PD‐L1‐low pulmonary sarcomatoid carcinoma: A case report
por: Taniguchi, Hirokazu, et al.
Publicado: (2021)

Alert Regarding Cisplatin-induced Severe Adverse Events in Cancer Patients with Xeroderma Pigmentosum
por: Sumiyoshi, Makoto, et al.
Publicado: (2017)

Diffuse alveolar hemorrhage with pseudoprogression during nivolumab therapy in a patient with malignant melanoma
por: Ikeda, Takaya, et al.
Publicado: (2018)

Pan‐HER inhibitors overcome lorlatinib resistance caused by NRG1/HER3 activation in ALK ‐rearranged lung cancer
por: Taniguchi, Hirokazu, et al.
Publicado: (2022)

Proportion of biopsy specimens containing a tumor when compared to all biopsy specimens by transbronchial biopsy
por: Takemoto, Shinnosuke, et al.
Publicado: (2023)

Intrathoracic amyloid tumors that presented as yellowish multinodular endobronchial protrusions with irregular vascularity and easy bleeding
por: Tomono, Hiromi, et al.
Publicado: (2019)

Adverse renal effects of anaplastic lymphoma kinase inhibitors and the response to alectinib of an ALK+ lung cancer patient with renal dysfunction
por: Shimada, Midori, et al.
Publicado: (2017)

Prediction of Anti-Cancer Drug-Induced Pneumonia in Lung Cancer Patients: Novel High-Resolution Computed Tomography Fibrosis Scoring
por: Gyotoku, Hiroshi, et al.
Publicado: (2020)

Phase II trial of a non‐platinum triplet for patients with advanced non‐small cell lung carcinoma (NSCLC) overexpressing ERCC1 messenger RNA
por: Takemoto, Shinnosuke, et al.
Publicado: (2019)

Dynamics of blood neutrophil‐related indices during nivolumab treatment may be associated with response to salvage chemotherapy for non‐small cell lung cancer: A hypothesis‐generating study
por: Soda, Hiroshi, et al.
Publicado: (2018)

Vildagliptin‐induced ground‐glass nodules mimicking lung metastases in a cancer patient receiving Lactobacillus probiotic supplementation
por: Tanaka, Yasuhiro, et al.
Publicado: (2020)

Remarkable response of nivolumab‐refractory lung cancer to salvage chemotherapy
por: Ogawara, Daiki, et al.
Publicado: (2017)

Premature phase II study of amrubicin as palliative chemotherapy for previously treated malignant pleural mesothelioma
por: Watanabe, Kageaki, et al.
Publicado: (2021)

Primary Mediastinal Large B-cell Lymphoma Exhibiting Endobronchial Involvement
por: Shimada, Midori, et al.
Publicado: (2016)

Presence of few PD‐1‐expressing tumor‐infiltrating immune cells is a potential predictor of improved response to salvage chemotherapy following nivolumab for non‐small cell lung cancer: An exploratory case series
por: Ogawara, Daiki, et al.
Publicado: (2018)

Exploring the ethical complexities of do‐not‐attempt‐resuscitation orders using the approach of advance care planning
por: Ogata, Ryo, et al.
Publicado: (2023)

Relationship between UGT1A1*27 and UGT1A1*7 polymorphisms and irinotecan‐related toxicities in patients with lung cancer
por: Fukuda, Minoru, et al.
Publicado: (2017)

Onset of pulmonary Epstein–Barr virus‐positive diffuse large B‐cell lymphoma in a patient with silicosis
por: Ogata, Ryosuke, et al.
Publicado: (2021)

Nivolumab infusion reaction manifesting as plantar erythema and pulmonary infiltrate in a lung cancer patient
por: Ogawara, Daiki, et al.
Publicado: (2017)

A refractory pleural effusion caused by a pleural capillary hemangioma
por: Akagi, Kazumasa, et al.
Publicado: (2021)

Efficacy and safety of amrubicin hydrochloride for treatment of relapsed small cell lung cancer
por: Ogawara, Daiki, et al.
Publicado: (2010)

Pitfalls in diagnosis with the use of circulating tumor‐derived epidermal growth factor receptor mutations in lung cancer harboring pretreatment T790M
por: Ogawara, Daiki, et al.
Publicado: (2017)

Podoplanin promotes progression of malignant pleural mesothelioma by regulating motility and focus formation
por: Takeuchi, Shinji, et al.
Publicado: (2017)

Amrubicin Monotherapy for Patients with Platinum-Refractory Gastroenteropancreatic Neuroendocrine Carcinoma
por: Ando, Takayuki, et al.
Publicado: (2015)

Efficacy and safety of amrubicin monotherapy after atezolizumab plus carboplatin and etoposide in patients with relapsed small-cell lung cancer
por: Imai, Hisao, et al.
Publicado: (2022)

Pulmonary pleomorphic carcinoma with few PD‐1‐positive immune cells and regulatory T cells that showed a complete response to nivolumab
por: Okamura, Kazuaki, et al.
Publicado: (2017)

Malignant Pleural Mesothelioma with Marked Lymphatic Involvement: A Report of Two Autopsy Cases
por: Ideguchi, Reiko, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_ssi1mifd6mu6obqqepjigtghtk